Cognitive Aging Liverman, Catharyn T; Yaffe, Kristine; Blazer, Dan G
04/2015
eBook
Odprti dostop
For most Americans, staying "mentally sharp" as they age is a very high priority. Declines in memory and decision-making abilities may trigger fears of Alzheimer's disease or other neurodegenerative ...diseases. However, cognitive aging is a natural process that can have both positive and negative effects on cognitive function in older adults - effects that vary widely among individuals. At this point in time, when the older population is rapidly growing in the United States and across the globe, it is important to examine what is known about cognitive aging and to identify and promote actions that individuals, organizations, communities, and society can take to help older adults maintain and improve their cognitive health.
Cognitive Aging assesses the public health dimensions of cognitive aging with an emphasis on definitions and terminology, epidemiology and surveillance, prevention and intervention, education of health professionals, and public awareness and education. This report makes specific recommendations for individuals to reduce the risks of cognitive decline with aging. Aging is inevitable, but there are actions that can be taken by individuals, families, communities, and society that may help to prevent or ameliorate the impact of aging on the brain, understand more about its impact, and help older adults live more fully and independent lives. Cognitive aging is not just an individual or a family or a health care system challenge. It is an issue that affects the fabric of society and requires actions by many and varied stakeholders. Cognitive Aging offers clear steps that individuals, families, communities, health care providers and systems, financial organizations, community groups, public health agencies, and others can take to promote cognitive health and to help older adults live fuller and more independent lives. Ultimately, this report calls for a societal commitment to cognitive aging as a public health issue that requires prompt action across many sectors.
Will SARS or another pandemic influenza reoccur and, if it does, have we learned how to manage pandemics more effectively? In SARS Unmasked risk communication expert Michael Tyshenko offers answers ...to this and other questions. Cathy Paterson, who worked as a nurse clinician during the Toronto SARS crisis, adds an important view from the frontlines. Their analysis reveals an out-of-control situation with mixed risk communication messages, a lack of leadership, and an overwhelmed health care system that was unable to both cope with the crisis in Toronto and provide adequate support for their most valuable employees at the time - health care workers.
Under the impact of various uncertainties, the potential operation risk of the distribution network is gradually gaining more and more attention in both security and economy. To comprehensively ...determine the risk level, an operational risk assessment method considering multiple risk factors is proposed. Firstly, probabilistic models are established including temporal distributions of electric vehicles and uncertainties of renewable energy. Secondly, a time-sequential security risk assessment method with several security indicators including overvoltage risk, undervoltage risk, line-overload risk and load-loss risk is established using probabilistic load flow and dynamical sensitivity weight analysis method. Thirdly, conditional value at risk model is presented for time-varying economic risk considering line-loss risk and operational profit or loss risk of distributed generations. Finally, a risk early warning standard is proposed to realise the visualisation of risk warning by defining the risk level and risk area. Simulations of different scenarios are conducted on the modified IEEE 34-bus radial test system and the results reveal that the proposed strategy is effective and practical.
This volume is part of the ongoing review of the underlying scientific bases for decision-making in chemical risk assessment by International Programme on Chemical Safety. It involves specific ...consideration of the area of dose-response assessment in the evaluation of information from toxicological studies in animals and from human clinical and epidemiological studies. It covers toxicants with threshold effects and those for which there may be no practical threshold, such as substances that are genotoxic and carcinogenic. The discussions are concerned with that subset of cause-effect relationships commonly referred to as dose-response models, which are typically used to characterize the biological effects of intentional (e.g. drugs and nutrients) and unintentional (e.g. contaminants) exposure to chemicals.This report is intended primarily to provide descriptive guidance for risk assessors in using dose-response modelling in hazard characterization. It will also provide mathematical modellers with an appreciation of issues to be considered when modelling in the context of the risk assessment process. Risk managers will be able to obtain a general understanding of the applications and limitations of dose-response modelling. For both risk assessors and risk managers, some considerations for communicating the results of risk assessments that use dose-response modelling are presented.
This innovative ethnographic study animates the racial politics that underlie genomic research into type 2 diabetes, one of the most widespread chronic diseases and one that affects ethnic groups ...disproportionately. Michael J. Montoya follows blood donations from "Mexican-American" donors to laboratories that are searching out genetic contributions to diabetes. His analysis lays bare the politics and ethics of the research process, addressing the implicit contradiction of undertaking genetic research that reinscribes race's importance even as it is being demonstrated to have little scientific validity. In placing DNA sampling, processing, data set sharing, and carefully crafted science into a broader social context, Making the Mexican Diabetic underscores the implications of geneticizing disease while illuminating the significance of type 2 diabetes research in American life.
Oncology in Primary Care is for primary care clinicians who need practical and concise information on caring for their patients with cancer.
Written in an easy-to-browse format, chapters cover risk ...factors, prevention, screening, prognosis, and surveillance strategies-valuable information that helps primary care clinicians advise their patients regarding therapeutic and end-of-life decisions and become true partners in the care of their patients with cancer.
Each chapter also includes an abundance of figures and tables to help clinicians find quick answers to questions commonly encountered in the primary care setting. Plus, a companion website is available allowing easy accessibility to the content.
Maintaining a balance between managing and assessing risk and upholding the required high standards of practice in health and social care can be demanding, particularly in the current climate of ...increased preoccupation with the difficult tensions between rights, protection and risk-taking. Good Practice in Assessing Risk is a comprehensive guide to good practice for those working with risk, covering a wide variety of health, social care and criminal justice settings including child protection, mental health, work with sex offenders and work with victims of domestic violence. The contributors discuss a range of key issues relating to risk including positive risk-taking, collaborating with victims and practitioners in the design of assessment tools, resilience to risk, and defensibility. The book also explores the role of bureaucracy in hindering high quality professional practice, complex decision-making in situations of stress or potential blame, and involving service users in assessment. This book reflects the latest policy and practice within health, social care and criminal justice and will be an invaluable volume to all professionals working in these fields.
This book is the first in the market to treat single- and multi-period risk measures (risk functionals) in a thorough, comprehensive manner. It combines the treatment of properties of the risk ...measures with the related aspects of decision making under risk.
Several drugs used in the treatment of mental diseases are associated with an increased risk of sudden cardiac death (SCD). A general cause-relationship between the intake of these drugs and SCD is ...unattainable, but numerous case reports of drug-induced malignant arrhythmia and epidemiological studies, associating the use of specific drugs with SCD, strongly support the presence of an increased risk. Whereas the absolute risk of drug-induced life-threatening arrhythmia may be relatively low, even small increments in risk of SCD may have a major health impact considering that millions of patients are treated with psychotropics. In subgroups of pre-disposed patients, e.g. patients with cardiac diseases or other co-morbidities, the elderly or patients treated with other negatively interacting drugs, the absolute risk of drug-induced arrhythmia may be considerable. On the other hand, several of the major mental disorders are associated with a large risk of suicide if untreated. The observed risk of malignant arrhythmia associated with treatment with psychotropic drugs calls for clinical guidelines integrating the risk of the individual drug and other potentially interacting risk factors. In this review, data from various authorities on the risk of arrhythmia associated with psychotropic medications were weighted and categorized into three risk categories. Additionally, we suggest a clinically applicable algorithm to reduce the risk of malignant arrhythmia in patients to be treated with psychotropic medications. The algorithm integrates the risk categories of the individual drugs and pre-disposing risk factors and suggests a prudent follow-up for patients with an increased risk. We believe this clinically manageable guideline might improve safety in the many and rapidly increasing number of patients on psychotropic drugs.
PDF